Veru Inc(VERU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:44 PM ET (Korea 10/28 05:44)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.61 | Insider Own | 12.1% | Shs Outstand | 17.1M | Perf Week | -4.2% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | -2.89% | Insider Trans | 0.09% | Shs Float | 15.0M | Perf Month | -9.7% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.25 | Inst Own | 17.03% | Short Float | 9.78% | Perf Quarter | 3.17% |
| Income | -0.01B | P/S | - | EPS this Y | 47.96% | Inst Trans | -6.43% | Short Ratio | 6.39 | Perf Half Y | -0.44% |
| Sales | 0.00B | P/B | 1.37 | EPS next 5Y | 33.14% | ROA | -43.85% | Short Interest | 1.47M | Perf YTD | 6.54% |
| Book/sh | 1.66 | P/C | 1.51 | EPS past 3/5Y | 50.51% 14.86% | ROE | -64.54% | 52W High | -68.89% ($7.33) | Perf Year | -40% |
| Cash/sh | 1.51 | P/FCF | - | Sales past 3/5Y | - | ROIC | -46.59% | 52W Low | 11.22% ($2.05) | Perf 3Y | -74.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.62% | Gross Margin | - | Volatility(W/M) | 4.09% 5.87% | Perf 5Y | -97.18% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | -76.49% |
| Dividend Ex-Date | 2014/4/28 | Quick Ratio | 4.42 | EPS Q/Q | 39.4% | Profit Margin | - | RSI (14) | 44.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.42 | Sales Q/Q | - | SMA20 | -4.09% ($2.38) | Beta | -1.21 | Target Price | $25.67 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/10 | SMA50 | -8.3% ($2.49) | Rel Volume | 0.69 | Prev Close | $2.21 |
| Employees | 20 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 6.25% - | SMA200 | -8.7% ($2.5) | Avg Volume(3M) | 0.23M | Price | $2.28 |
| IPO | 1990/7/19 | Option/Short | Yes/Yes | Trades | 887 | Volume | 157,227 | Change | 3.17% |
💊 This is a late-stage clinical biotech developing a combination GLP-1 obesity/sarcopenia treatment (enobosarm) and a breast cancer therapy. The goal is to achieve weight loss without muscle loss when combined with a GLP-1 drug, with Phase 2b interim results in 2027 serving as the biggest potential stock catalyst.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
VERU has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #436 of 594 in the industry
Based on market cap of $39M.
FAQ
What kind of company is VERU?
VERU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VERU?
The market cap of VERU is approximately $39M, ranking 4,974 within its sector.
What is the 52-week high and low for VERU?
VERU has recorded a 52-week high of $7.33 and a low of $2.05.
